The hybrid congress will take place from 1-4 June in Copenhagen, as well as virtually
He is an experienced professional in the pharmaceutical industry with about 30 years of progressive experience
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs
Coordinated by the Medical University of Vienna, a consortium of 13 leading European organizations including university hospitals, research institutions and healthcare companies will conduct the 5-year project co-funded by Horizon Europe.
Lupin’s subsidiary in Philippines, Multicare Pharmaceuticals, will file for marketing approval and be responsible for distribution and commercialization of the biosimilars once approved.
Subscribe To Our Newsletter & Stay Updated
